Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone
Cancer Medicine Aug 02, 2021
Zhu S, Ni Y, Sun G, et al. - The researchers wanted to use ddPCR to quantify plasma exosomal class III β-tubulin (βIII-tubulin, TUBB3, encoded by the TUBB3 gene) mRNA expression in patients with metastatic castration-resistant prostate cancer (mCRPC) and investigate the relationship between this expression and abiraterone efficacy. Blood samples were collected prospectively from 52 mCRPC patients receiving abiraterone as first-line therapy to assess plasma exosomal TUBB3 mRNA expression levels prior to starting abiraterone. The exosomal TUBB3 mRNA expression level is linked to poor PSA-PFS of abiraterone in mCRPC patients. Exosomal TUBB3 detection may be useful in their management.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries